尼奥体
聚山梨酯
阳离子聚合
药物输送
化学
色谱法
肺表面活性物质
小泡
有机化学
膜
生物化学
作者
Axel Kattar,Ana Quelle‐Regaldie,Laura Sánchez,Ángel Concheiro,Carmen Alvarez‐Lorenzo
出处
期刊:Pharmaceutics
[MDPI AG]
日期:2023-04-14
卷期号:15 (4): 1247-1247
被引量:25
标识
DOI:10.3390/pharmaceutics15041247
摘要
The aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3-trimethylammonium propane. The niosomes were characterized using dynamic light scattering, zeta-potential, and transmission electron microscopy to determine their size (80 nm; polydispersity index 0.3 to 0.5), charge (−23 to +40 mV), and shape (spherical). The encapsulation efficiency (99.76%) and the release (75% drug release over 20 days) were measured with dialysis. The ocular irritability potential (non-irritating) was measured using the Hen’s Egg Test on the Chorioallantoic Membrane model, and the blood glucose levels (on par with positive control) were measured using the gluc-HET model. The toxicity of the niosomes (non-toxic) was monitored using a zebrafish embryo model. Finally, corneal and scleral permeation was assessed with the help of Franz diffusion cells and confirmed with Raman spectroscopy. Niosomal permeation was higher than an unencapsulated drug in the sclera, and accumulation in tissues was confirmed with Raman. The prepared niosomes show promise to encapsulate and carry epalrestat through the eye to meet the need for controlled drug systems to treat the diabetic eye.
科研通智能强力驱动
Strongly Powered by AbleSci AI